A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data - supplementary material

Supplemental Table 1. Participating countries and patient enrollment (full analysis set) 
 Supplemental Table 2. Prior anticancer therapy and prior/relevant medical conditions (full analysis set). 
 Supplemental Table 3. Protocol deviations (full analysis set). 
 Supplemental Table 4. Concomitant medications* (full analysis set). 
 Supplemental Table 5. Baseline patient demographics, characteristics, and EGFR mutation data according to EGFR mutation status combination subgroup.